Cantor Fitzgerald Reiterates Overweight on Editas Medicine, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Editas Medicine (NASDAQ:EDIT) and maintained a $14 price target.

August 29, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Editas Medicine and maintained a $14 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Editas Medicine. The maintained price target of $14 suggests that the analyst believes the stock is undervalued at current levels. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100